F10 and atrial fibrillation: ,4 Indeed, in the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study on 14,171 patients with AF, after a median follow-up of 1.9 years, <10% of the cardiovascular deaths were associated with ischemic stroke or systemic embolism,3 whereas, in a French cohort of 8,962 patients with AF, after a median follow-up of 1.3 years, only 7% of deaths were caused by stroke.4